3D-MBI aims to deliver a disruptive Molecular Breast Imaging (MBI) device for breast cancer diagnosis, based on cadmium zinc telluride (CZT) strip drift detectors (DTU’s patented technology). 3D-MBI will bring disruptive performance to the MBI field through high tumour detection sensitivity, combined with 3d positional information– opening possibilities for guided biopsies and treatment. We intend to deliver a detector module for MBI, thus triggering overall social and economic potential impact.

Selective Laser Sintering (Metal 3D Print) anvendes i dag industrielt. Men begrænset materialeudvalg, præcision, produktionshastighed og stort efterbearbejdningsbehov mindsker anvendelighed og udbredelse. AddiFab har udviklet Printed Mould Casting (PMC), en fleksibel produktionsplatform baseret på 3D-printede skal-forme. Disse fyldes med ønsket materiale (flydende gummi, metal – eller keramikpasta) og ofres i færdigbearbejdningen af den enkelte komponent. PMC fjerner metal 3D prints begrænsninger og er eftervist i pilot-forsøg. Men væsentlige mangler skal adresseres før metoden kan anvendes industrielt: a. De enkelte delprocesser skal karakteriseres, og procesparametre skal kunne modelleres og simuleres ved indkøring af nye emner for at sikre høj first-time yield b. De enkelte delprocesser skal kunne overvåges og ændres real-time for at understøtte automatisk korrektion af afvigelser fra specificerede parametre c. Produktionsdata skal kunne opsamles og analyseres for at understøtte automatiseret optimering og iterativ forbedring af modellering og simulering Projektets formål er at videreudvikle PMC til en integreret, automatiseret produktionsplatform til industriel fremstilling af præcisionsemner i gummi, metal og keramik

I projektet udvikles en hybrid pasteuriseringsløsning og robotgribeløsning, der muliggør en hurtig og fleksibel tappeløsning til drikkevarer uden egenkonservering og med komplekse proteinstrenge. Løsningen vil kunne levere samme renhed som langt dyrere og langsommere autoklaveløsninger, samt en avanceret sensorpakke der muliggør automatiseret dokumentation af alle delprocesser i produktionen. Løsningen vil også muliggøre rentabel produktion af selv meget små højkvalitetsproduktserier.

Daglig motion er vigtig når man kommer op i alderen. 30 minutter daglig motion øger chancen for et længere liv med højere livskvalitet – men mange følger ikke anbefalingerne. 4Mvideo er et videobaseret cykelmotionssystem til seniorer (se film www.4mvideo.dk), som øger motivation og muligheder for motion. Det består af et website med cykelvideoer og en 4Mvideo-app, der installeret på en tablet-computer, kan afspille cykelvideoer i takt med pedaltrådet på motionscykel med påmonteret kadancesensor.

Today, when a fetal malformation is detected during pregnancy, current technologies offer an explanation in less than one in five cases. This means that couples may decide to terminate or continue a pregnancy without knowing if the malformation is a symptom of a multi-organ syndrome, a treatable disease or a single malformation. Furthermore, in on-going pregnancies, the prenatal surveillance, delivery, and post-natal treatment and care are carried out without knowing the specific diagnosis/prognosis of the child, which often leads to over- or under-treatment of the child, failed or ineffective therapeutic interventions, parental anxiety and feelings of guilt, as well as uncertainty and frustration amongst health professionals. We propose personalised medicine for the unborn child and family by implementing the newest genetic technologies - Whole Exome Sequencing and Whole Genome Sequencing - as a first line diagnostic tool for all fetal malformations that are currently unexplained.

Today, when a fetal malformation is detected during pregnancy, current technologies offer an explanation in less than 1 in 5 cases. This means that couples may decide to terminate or continue a pregnancy without knowing if the malformation is a symptom of a multi-organ syndrome, a treatable disease or a single malformation. Furthermore, in on-going pregnancies, the prenatal surveillance, delivery, and post-natal treatment and care are carried out without knowing the specific diagnosis/prognosis of the child, which often leads to over- or under-treatment of the child, failed or ineffective therapeutic interventions, parental anxiety and feelings of guilt, as well as uncertainty and frustration amongst health professionals. We propose personalised medicine for the unborn child and family by implementing the newest genetic technologies - Whole Exome Sequencing and Whole Genome Sequencing - as a first line diagnostic tool for all fetal malformations that are currently unexplained.

The NORDTREAT project will build on the achievements within recent large-scale European initiatives that includes cross-disciplinary collaborations between academia, hospitals, biomedical companies and patient organisations. The overall aim is to improve Inflammatory bowel disease (IBD) patients' prognosis and quality of life by introducing a novel personalized medicine algorithm that is based on recently generated -omics data. IBD is a disease entity of unknown origin, characterized by a chronic inflammation in the gastrointestinal tract. IBD is increasing, especially among teenagers, and today 0.5-1% of the Nordic population is affected. The disease course varies from an indolent course to an aggressive, treatment refractory disease, with need of repeated hospital admissions, surgery and increased risk of comorbidity including cancer. Thus, IBD have severe consequences for many affected individuals, including life-long medication, hospitalizations, recurring sick-leaves, and surgic

The NORDTREAT project will build on the achievements within recent large-scale European initiatives that includes cross-disciplinary collaborations between academia, hospitals, biomedical companies and patient organisations. The overall aim is to improve Inflammatory bowel disease (IBD) patients' prognosis and quality of life by introducing a novel personalized medicine algorithm that is based on recently generated -omics data. In this project, our aim is to selectively identify patients with a poor prognosis based on a novel objective protein signature, recently identified by members of the NORDTREAT team, and adapt the treatment in these patients to minimize disease-induced damage on the gastrointestinal tract and to improve longterm disease outcomes. NORDTREAT exploitation plan includes the development of this protein signature into a diagnostic application, implementation of this diagnostic application as a prognostic tool in healthcare and exploration of potential biomarkers.